Gemcitabine

製品コードS1714 別名：LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW)：263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(18)

カスタマーフィードバック(4)

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NWrB[2RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTPTWM2OD1yLkCwNFQ2QCCwTR?= MYDTRW5ITVJ?
ES4 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rwb2lEPTB;MD6wNFA3PTNibl2= MXrTRW5ITVJ?
ACHN NYjkcVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMECwPFg4KG6P NGDqb3BUSU6JRWK=
KYSE-510 NGfmO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMECwPVc2KG6P NWTxboR3W0GQR1XS
EW-7 NWX4WohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmzTWM2OD1yLkCwNlU5KG6P NVfJSZNsW0GQR1XS
BFTC-905 NXfKSWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qyb2lEPTB;MD6wNFUyPSCwTR?= MnexV2FPT0WU
KE-37 MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH0SXY4UUN3ME2wMlAxPTZzIH7N M1uy[3NCVkeHUh?=
SBC-5 M2DTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEC1O{BvVQ>? NGXEcnhUSU6JRWK=
NKM-1 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HyTWlEPTB;MD6wNFcxQSCwTR?= Mnf1V2FPT0WU
RH-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvpTWM2OD1yLkCwO|E5KG6P M2rmU3NCVkeHUh?=
ALL-PO NGPFO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEewTJJKSzVyPUCuNFA5OyCwTR?= M2\aW3NCVkeHUh?=
QIMR-WIL MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTjTWM2OD1yLkCwPFk1KG6P NWj0e5lCW0GQR1XS
A375 M1jlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEC5PVUhdk1? Ml\MV2FPT0WU
SIG-M5 NGHUNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni4TWM2OD1yLkCxNFQhdk1? NUHiV4RyW0GQR1XS
KGN NYXpZ5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PNUWlEPTB;MD6wNVA5KG6P MVPTRW5ITVJ?
EW-13 NVjBemxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXCR4hKSzVyPUCuNFEyOiCwTR?= M2r5[3NCVkeHUh?=
NCI-SNU-1 NGXkZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;UU2lEPTB;MD6wNVYhdk1? MnqxV2FPT0WU
PSN1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX5dWVKSzVyPUCuNFE3PSCwTR?= MnfxV2FPT0WU
HUTU-80 NWLaO5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;W[2JKSzVyPUCuNFE3PiCwTR?= M{HZOHNCVkeHUh?=
EW-16 M4f2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEKzJI5O NITyUlhUSU6JRWK=
786-0 M1O4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K0[GlEPTB;MD6wNlMhdk1? NVLvPZh3W0GQR1XS
ES1 M1HFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Zb|BiUUN3ME2wMlAzPjhibl2= Mlr4V2FPT0WU
RKO MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HGOGlEPTB;MD6wNlc6KG6P Mny0V2FPT0WU
ESS-1 NELjfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPmTWM2OD1yLkCyPFYhdk1? NF7JTWZUSU6JRWK=
SK-UT-1 M3jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXHTWM2OD1yLkCyPVchdk1? NF7KV3FUSU6JRWK=
LB2241-RCC M1T3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfndmZJUUN3ME2wMlA{OThibl2= NFrvPFlUSU6JRWK=
CHL-1 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrRTWM2OD1yLkCzNlQhdk1? MWXTRW5ITVJ?
SW1783 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEOzOkBvVQ>? NYPqXXhKW0GQR1XS
MEL-JUSO M3ywZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEO5NUBvVQ>? M3LCcnNCVkeHUh?=
HT-29 M{LqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XS[2lEPTB;MD6wOFE{KG6P M4j4WnNCVkeHUh?=
SNG-M MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnSOXFKSzVyPUCuNFQzPSCwTR?= NULzOZVvW0GQR1XS
TE-15 NVHkWXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPxUmpKSzVyPUCuNFQ3PCCwTR?= NIfiblBUSU6JRWK=
HOS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nHXmlEPTB;MD6wOFghdk1? M2DIbnNCVkeHUh?=
BB65-RCC NIPtbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rTNmlEPTB;MD6wOVEzKG6P M3vzSnNCVkeHUh?=
HCE-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD1yLkC1Nlghdk1? NFjUR2FUSU6JRWK=
MHH-ES-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP1TWM2OD1yLkC1N|Ehdk1? M3jqfnNCVkeHUh?=
RPMI-7951 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEW0NUBvVQ>? MoftV2FPT0WU
IST-SL2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP5W455UUN3ME2wMlA2QDRibl2= M3fDPHNCVkeHUh?=
CMK NUXmeWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH4TWM2OD1yLkC1PFYhdk1? NUjCRnVvW0GQR1XS
GR-ST NInwcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[0b5dSUUN3ME2wMlA2QTVibl2= NGLFSWZUSU6JRWK=
NALM-6 NX;Hd|I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwME[yNkBvVQ>? MWjTRW5ITVJ?
RPMI-6666 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLMTWM2OD1yLkC2OVIhdk1? NIrhbHlUSU6JRWK=
LC-2-ad NG\l[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBTWM2OD1yLkC2OVMhdk1? M1L4SnNCVkeHUh?=
ARH-77 NIP1OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj2eGlbUUN3ME2wMlA4OTFibl2= NYjFZYMxW0GQR1XS
IST-MEL1 NHrwTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEeyOkBvVQ>? NVX3bZZvW0GQR1XS
SW1710 NEjBeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETGZZFKSzVyPUCuNFc2OSCwTR?= Mkj1V2FPT0WU
DEL NXfico1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon1TWM2OD1yLkC4PFchdk1? MYjTRW5ITVJ?
AGS NVq0dWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLiTWM2OD1yLkC5NFIhdk1? MXnTRW5ITVJ?
NCI-H2122 NHn2b5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfIVZBKSzVyPUCuNFk1PiCwTR?= MlvOV2FPT0WU
HSC-4 M1HjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnwS2JKSzVyPUCuNVAzKG6P NIrofYJUSU6JRWK=
AM-38 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrvcYFLUUN3ME2wMlEzOSCwTR?= MXrTRW5ITVJ?
769-P M1jtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHmWGhQUUN3ME2wMlEzOyCwTR?= MVzTRW5ITVJ?
RT-112 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTMRVR4UUN3ME2wMlEzPyCwTR?= MWHTRW5ITVJ?
MCF7 NIDr[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTRTWM2OD1yLkGzOkBvVQ>? M3;aeXNCVkeHUh?=
IGROV-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMUS1JI5O M1\nZ3NCVkeHUh?=
OCI-AML2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XWZmlEPTB;MD6xOFchdk1? MUHTRW5ITVJ?
NCI-H1299 NYnQNVA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwTWM2OD1yLkG1O{BvVQ>? MknvV2FPT0WU
A431 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPWTWM2OD1yLkG4N{BvVQ>? MYrTRW5ITVJ?
SW982 NHjKUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LDbWlEPTB;MD6yNVMhdk1? MoTxV2FPT0WU
BB30-HNC NHnzUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3zTWM2OD1yLkKzNUBvVQ>? MXzTRW5ITVJ?
ACN NXjaXVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOwdXAyUUN3ME2wMlI1PCCwTR?= MnfuV2FPT0WU
647-V MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;XTWM2OD1yLkK0PEBvVQ>? NGXaOmFUSU6JRWK=
SK-PN-DW M4r3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMk[2JI5O MUjTRW5ITVJ?
LCLC-97TM1 NWS1UXhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV33NpNpUUN3ME2wMlI3PyCwTR?= M2jWb3NCVkeHUh?=
LB1047-RCC MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIiweGxKSzVyPUCuNlY6KG6P MknZV2FPT0WU
A2780 NFm0SFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5XY8zUUN3ME2wMlI4KG6P MU\TRW5ITVJ?
C-33-A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMkezJI5O MULTRW5ITVJ?
NCI-H2228 NGjTSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DmemlEPTB;MD6zNVQhdk1? MnfiV2FPT0WU
TE-5 NX;ybodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwM{G2JI5O MUDTRW5ITVJ?
HC-1 NEX0XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLkTWM2OD1yLkOyO{BvVQ>? MmfsV2FPT0WU
SK-MES-1 NYPVWJh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnldJV1UUN3ME2wMlMzQCCwTR?= NYHqRWdwW0GQR1XS
NCI-H1355 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITIdJdKSzVyPUCuN|gyKG6P MVfTRW5ITVJ?
YKG-1 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfzXmZNUUN3ME2wMlQyQSCwTR?= NX3FTXNEW0GQR1XS
RS4-11 NUTTSnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2wUmIxUUN3ME2wMlQ{OyCwTR?= M1rNPHNCVkeHUh?=
Daoy NFOxS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT4boxlUUN3ME2wMlQ2PiCwTR?= MkDhV2FPT0WU
A3-KAW MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm0WJJKSzVyPUCuOVUyKG6P MnjqV2FPT0WU
SK-MEL-30 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwNUW0JI5O M4LNfXNCVkeHUh?=
U031 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TnXWlEPTB;MD61OlUhdk1? NHTsXFNUSU6JRWK=
SK-LMS-1 M4HEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnYXoFKSzVyPUCuOVc5KG6P Ml3EV2FPT0WU
ES6 NF\YNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNUi2JI5O M4HTNHNCVkeHUh?=
EoL-1-cell NHTDcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwNkG2JI5O M1T0dnNCVkeHUh?=
NCI-H2009 M4LRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHscWpWUUN3ME2wMlYyQSCwTR?= M3jUbHNCVkeHUh?=
A4-Fuk NUHSeINqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO5OXJZUUN3ME2wMlYzPiCwTR?= MWnTRW5ITVJ?
KYSE-270 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTzWmpqUUN3ME2wMlY{PCCwTR?= Mn7UV2FPT0WU
SK-LU-1 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnXTWM2OD1yLk[1OUBvVQ>? NV\SV2szW0GQR1XS
SW872 NWHTUnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwN{[1JI5O NHzzRYVUSU6JRWK=
ES8 NWnI[oN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LQ[2lEPTB;MD63PEBvVQ>? M3LGR3NCVkeHUh?=
G-402 NUHRN5dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LFRWlEPTB;MD63PFQhdk1? MX3TRW5ITVJ?
ATN-1 NW\sbYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTlPXdKSzVyPUCuPFA4KG6P Ml;JV2FPT0WU
DoTc2-4510 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XzSGlEPTB;MD65NFEhdk1? M3nUZnNCVkeHUh?=
MES-SA MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\VSJl[UUN3ME2wMlkxPSCwTR?= MmTLV2FPT0WU
SF268 NUnsemtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f2NmlEPTB;MD65Nlchdk1? MmDRV2FPT0WU
SF539 NFP3fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7WTWM2OD1zLkCyJI5O MXfTRW5ITVJ?
NB69 NF;idINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HhdmlEPTB;MT6wOUBvVQ>? MofyV2FPT0WU
8505C Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO4fGNKSzVyPUGuNFYhdk1? MnLRV2FPT0WU
CAL-12T NHT1fItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\jWZFHUUN3ME2xMlA5KG6P MlrWV2FPT0WU
BHY Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TlVGlEPTB;MT6xOEBvVQ>? MYnTRW5ITVJ?
LB647-SCLC MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwMUigcm0> NETCO2RUSU6JRWK=
CAL-62 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rPPGlEPTB;MT6yNkBvVQ>? MlzDV2FPT0WU
MEG-01 NHuxPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jUS2lEPTB;MT6yO{BvVQ>? M3jGS3NCVkeHUh?=
MG-63 NWDFOplLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwM{Ogcm0> NVjNdXRtW0GQR1XS
SW620 NVHoUZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwM{Wgcm0> Ml6xV2FPT0WU
A388 NVGzfoZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwM{[gcm0> NEH6OmNUSU6JRWK=
BCPAP MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHmTWM2OD1zLkS1JI5O MVrTRW5ITVJ?
P30-OHK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwNE[gcm0> MnPVV2FPT0WU
Ca9-22 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwNUSgcm0> NI\3TnVUSU6JRWK=
VMRC-RCZ NGfPbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j6RmlEPTB;MT61OEBvVQ>? M1PtfHNCVkeHUh?=
LOXIMVI Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PIZWlEPTB;MT62JI5O NWPGUW54W0GQR1XS
L-540 NVXoTXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnxZ|hKSzVyPUGuOkBvVQ>? NXPD[JVyW0GQR1XS
NTERA-S-cl-D1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTTWM2OD1zLk[0JI5O NH\i[XlUSU6JRWK=
MFH-ino NXzjVWVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULW[Yx1UUN3ME2xMlY3KG6P M4TCW3NCVkeHUh?=
Calu-6 NVjVZnJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOzTWM2OD1zLkezJI5O MlLTV2FPT0WU
HEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwN{mgcm0> M4fKdnNCVkeHUh?=
CAL-33 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTmcFRKSzVyPUGuPFkhdk1? MYTTRW5ITVJ?
HSC-3 NV\WSVF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ETWM2OD1zLkmxJI5O NUHyNIV5W0GQR1XS
KU812 M3rrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDTXlhKSzVyPUGuPVEhdk1? NVnQcIxXW0GQR1XS
EB2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PNU2lEPTB;Mj6wNUBvVQ>? MnfOV2FPT0WU
SR M{j3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nadWlEPTB;Mj6xNkBvVQ>? MX3TRW5ITVJ?
NCI-H2087 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j4VWlEPTB;Mj6xOEBvVQ>? M{\Y[HNCVkeHUh?=
H4 MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\VXnNKSzVyPUKuNVghdk1? NEfuPIpUSU6JRWK=
EW-1 NYO1fIJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX6VpNQUUN3ME2yMlIzKG6P NHzDTIpUSU6JRWK=
MC-IXC Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPwTWM2OD1{LkK2JI5O NELnToJUSU6JRWK=
NCI-H727 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r1V2lEPTB;Mj61NUBvVQ>? NUHrdWZvW0GQR1XS
MRK-nu-1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X6eGlEPTB;Mj61O{BvVQ>? NIj4R4xUSU6JRWK=
COLO-668 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rke2lEPTB;Mj62OkBvVQ>? Ml\KV2FPT0WU
CGTH-W-1 NF3sPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnsRppKSzVyPUKuO|Ihdk1? NXPsUYdqW0GQR1XS
CHP-212 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITwRZRKSzVyPUKuO|Uhdk1? MWXTRW5ITVJ?
GI-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe1Z4QxUUN3ME2yMlc3KG6P M4P6U3NCVkeHUh?=
HCC1806 M4HxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD1{LkmxJI5O M3HNdHNCVkeHUh?=
HLE MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LFfWlEPTB;MzDuUS=> MVHTRW5ITVJ?
HSC-2 M2PCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13mNmlEPTB;Mz6wN{BvVQ>? NU\4foptW0GQR1XS
DMS-273 M1PDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\4cJBKSzVyPUOuNFchdk1? M1rtbHNCVkeHUh?=
DU-4475 M1HuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPlOpE1UUN3ME2zMlE1KG6P NWrPc|dMW0GQR1XS
LXF-289 M2fUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNwM{Ggcm0> NX;BWmh{W0GQR1XS
PANC-03-27 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD1|LkWxJI5O MmLZV2FPT0WU
GAMG MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoruTWM2OD1|Lke0JI5O M1fU[XNCVkeHUh?=
NCI-H522 M2DiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwM{Sgcm0> M4m3THNCVkeHUh?=
SW626 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwNE[gcm0> M1zQW3NCVkeHUh?=
HT-144 M4\aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnETWM2OD12LkmyJI5O MYnTRW5ITVJ?
MEL-HO M3fRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnSdG9OUUN3ME21MlE3KG6P MojDV2FPT0WU
BE-13 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LGWGlEPTB;NT6yNUBvVQ>? NEXrXmVUSU6JRWK=
VA-ES-BJ M4HDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF65SmVKSzVyPUWuNlYhdk1? MmPBV2FPT0WU
NCI-H441 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;OTWM2OD13Lk[gcm0> NWHBemx2W0GQR1XS
KP-4 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP3[mllUUN3ME21MlYyKG6P NEXrZolUSU6JRWK=
LoVo MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInJPJlKSzVyPUWuO|Ehdk1? MYrTRW5ITVJ?
HT-1080 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HnVmlEPTB;NT64N{BvVQ>? MVHTRW5ITVJ?
GB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnoTWM2OD13Lki0JI5O MVPTRW5ITVJ?
IA-LM NYHXOGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\TTWM2OD13LkmxJI5O M4nUe3NCVkeHUh?=
8-MG-BA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O0RWlEPTB;NT65N{BvVQ>? NVTGZYVmW0GQR1XS
SK-HEP-1 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nzWmlEPTB;Nj6xOEBvVQ>? M33wTXNCVkeHUh?=
697 NEjKN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPrZ2pKSzVyPU[uNlUhdk1? NX3POGN6W0GQR1XS
KYSE-450 M1:1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwM{Kgcm0> M1TXOHNCVkeHUh?=
HCC2998 NYf1b|RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfvPI5KSzVyPU[uN|Qhdk1? Mk\OV2FPT0WU
HD-MY-Z NWXjfHRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H3[2lEPTB;Nj62PEBvVQ>? NUjxS4N[W0GQR1XS
OS-RC-2 M3vqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HhNmlEPTB;Nj62PEBvVQ>? MlPtV2FPT0WU
SF126 NHzxeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrJTWM2OD15LkC1JI5O M1LZSXNCVkeHUh?=
Ca-Ski NGnjNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X4VmlEPTB;Nz6wPUBvVQ>? Mli2V2FPT0WU
NCI-H358 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[4cWlEPTB;Nz6xOkBvVQ>? M3\RS3NCVkeHUh?=
J82 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPxcXZKSzVyPUeuOFEhdk1? MkjEV2FPT0WU
NCI-H2342 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTdwNkOgcm0> MnvOV2FPT0WU
OVCAR-8 NWPlS|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTdwOTDuUS=> NWK1PYd7W0GQR1XS
TE-8 M4fHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRThibl2= Mn3mV2FPT0WU
ETK-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrrRYVMUUN3ME24MlA5KG6P NXfEcWdnW0GQR1XS
HAL-01 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXHUndGUUN3ME24MlIhdk1? NHnJNWZUSU6JRWK=
KYSE-150 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfPTWM2OD16LkS3JI5O NGK5ZndUSU6JRWK=
NCI-H810 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;IXotKSzVyPUiuOVYhdk1? NYTZcYJsW0GQR1XS
ONS-76 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRThwNkigcm0> MWrTRW5ITVJ?
NMC-G1 M1S1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjXXmlzUUN3ME24Mlc3KG6P NHPzbYpUSU6JRWK=
C3A M1:xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLGTWM2OD16Lki0JI5O MUTTRW5ITVJ?
PA-1 NF7WPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWy[ItKSzVyPUiuPVkhdk1? NY\YbWNkW0GQR1XS
SH-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\aTGlEPTB;OT6wNkBvVQ>? NWnCVJg6W0GQR1XS
EFO-27 NWnzU4VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXXTWM2OD17LkC1JI5O MmPCV2FPT0WU
CAPAN-1 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;PTWM2OD17LkKzJI5O NH\vUIVUSU6JRWK=
DU-145 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTlwMkmgcm0> NIOyb5hUSU6JRWK=
A101D M4mzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rEWWlEPTB;OT6zO{BvVQ>? NHrrTm9USU6JRWK=
ST486 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnKZoxlUUN3ME25MlQyKG6P NYHrSok6W0GQR1XS
NCI-H1437 NFzNPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDMb5VKSzVyPUmuOFIhdk1? M4LUOnNCVkeHUh?=
HGC-27 NIDreHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fzcWlEPTB;OT62JI5O NHLkbmZUSU6JRWK=
8305C M1PVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvUXlV3UUN3ME25MlY1KG6P MmXwV2FPT0WU
OCUB-M NYHVT5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXTTWM2OD1zMD6wN{BvVQ>? NYDJWllpW0GQR1XS
COLO-679 NXixXYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXNR5VKSzVyPUGwMlA4KG6P MUHTRW5ITVJ?
Detroit562 NGSwbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TN[2lEPTB;MUCuOFIhdk1? MlrrV2FPT0WU
A204 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fNW2lEPTB;MUGuNVYhdk1? NVzVT|B[W0GQR1XS
NCI-H1734 NIK0VXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\YTWM2OD1zMT6yPUBvVQ>? M{f2cnNCVkeHUh?=
MC-CAR NXjHS3c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWR5NKSzVyPUGxMlU5KG6P MU\TRW5ITVJ?
NCI-H2170 NV:zeHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnjSoNKSzVyPUGxMlk4KG6P MULTRW5ITVJ?
NCI-SNU-5 NIGxU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnuRpg4UUN3ME2xNk4yOyCwTR?= MUnTRW5ITVJ?
HCE-T MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXYTWM2OD1zMj60NkBvVQ>? NFLTVGNUSU6JRWK=
KYSE-180 Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnkPXlzUUN3ME2xNk45OSCwTR?= MmnOV2FPT0WU
C8166 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPnSoRKSzVyPUGzMlA5KG6P MVXTRW5ITVJ?
NCI-H460 M3X6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL5RoVKUUN3ME2xN{42PCCwTR?= NU\1cJVPW0GQR1XS
SNU-449 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KzZmlEPTB;MUOuO|chdk1? NHmwNIVUSU6JRWK=
MDA-MB-468 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW5c3lKSzVyPUG0MlEzKG6P NHH0VJFUSU6JRWK=
COR-L23 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPOeY1KSzVyPUG0MlE{KG6P NXq2fHVsW0GQR1XS
CTV-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF2LkG0JI5O NV2yVWd{W0GQR1XS
BL-41 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkO3JI5O M1L3OXNCVkeHUh?=
IGR-1 M1rUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjNS411UUN3ME2xOE41OiCwTR?= MYLTRW5ITVJ?
TK10 M{P4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTBTWM2OD1zND60PUBvVQ>? Mk\IV2FPT0WU
REH M4\ScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLKTWM2OD1zND61NUBvVQ>? NGns[|VUSU6JRWK=
LU-139 M1ixcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC4TWM2OD1zND61PUBvVQ>? NXfiRnVJW0GQR1XS
KP-N-YS NF76N5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq4T2FKSzVyPUG0Mlk4KG6P M{K3eXNCVkeHUh?=
PANC-10-05 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjBTHhnUUN3ME2xOU4{QCCwTR?= NIT5W4RUSU6JRWK=
HL-60 NVXqNmNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELmOVBKSzVyPUG1MlY6KG6P NFHRXFRUSU6JRWK=
T84 M4LpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\PZ2lEPTB;MUWuPVYhdk1? MX7TRW5ITVJ?
RPMI-8226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTofGNnUUN3ME2xOk4xOiCwTR?= M1TWcnNCVkeHUh?=
UM-UC-3 Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fDcGlEPTB;MU[uNVYhdk1? MlezV2FPT0WU
TE-10 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7MTWM2OD1zNj6yNUBvVQ>? MljWV2FPT0WU
CAL-148 NVywWYFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MortTWM2OD1zNz6yN{BvVQ>? M1\0VHNCVkeHUh?=
BV-173 M{\JS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LRbmlEPTB;MUeuNlchdk1? NG\pbFRUSU6JRWK=
Calu-3 M4Tnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfZZ5RKSzVyPUG3MlI6KG6P MoDUV2FPT0WU
RPMI-2650 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxW3N[UUN3ME2xO{42QSCwTR?= MlTYV2FPT0WU
MKN45 M4XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHvTWM2OD1zNz63N{BvVQ>? NY\Ddmo2W0GQR1XS
NUGC-3 NGrZSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13hVmlEPTB;MUiuN|Qhdk1? MnnuV2FPT0WU
NCI-H520 NIXxcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF6Lke3JI5O NHzi[mhUSU6JRWK=
CCRF-CEM M{i2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq0dYRKSzVyPUG4Mlg2KG6P MV\TRW5ITVJ?
NCI-H2405 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX21fYR{UUN3ME2xPU4yKG6P NHvxepdUSU6JRWK=
ES7 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj5PJFKSzVyPUG5Mlc3KG6P MlfEV2FPT0WU
BPH-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIruNGVKSzVyPUKwMlI5KG6P M{DxNnNCVkeHUh?=
SAS M1PMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTqTWM2OD1{MD61JI5O Mn;SV2FPT0WU
HuCCT1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJyLkW4JI5O MUDTRW5ITVJ?
LOUCY MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f0NWlEPTB;MkCuOlYhdk1? NHfGO3RUSU6JRWK=
NCI-H292 NEXhdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn4fYtKSzVyPUKwMlc6KG6P MmCxV2FPT0WU
G-361 M2rrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJzLkC3JI5O MkTzV2FPT0WU
M059J NEXaOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjHNHVKSzVyPUKxMlA5KG6P MkfiV2FPT0WU
NCI-H1651 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHvSYI6UUN3ME2yNU4yOSCwTR?= MVXTRW5ITVJ?
KALS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJzLkO5JI5O NYL5XIE{W0GQR1XS
DJM-1 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHBfmlKSzVyPUKxMlU6KG6P NGL3T4ZUSU6JRWK=
AU565 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rNWGlEPTB;MkGuPFMhdk1? NYL5RlBUW0GQR1XS
HCC38 NGD4SXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPVfm5xUUN3ME2yNU46PSCwTR?= MlG2V2FPT0WU
U251 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXXTWM2OD1{Mj6yO{BvVQ>? NHv0co5USU6JRWK=
ABC-1 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XmTmlEPTB;MkKuOlUhdk1? MlrOV2FPT0WU
SK-NEP-1 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDzTWM2OD1{Mj65N{BvVQ>? NGnMeYZUSU6JRWK=
CESS NHfuNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTRTWM2OD1{Mz6xPUBvVQ>? MoO3V2FPT0WU
MIA-PaCa-2 NX7XZYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ|LkO2JI5O NEjRdJNUSU6JRWK=
SUP-T1 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\OTWM2OD1{Mz60O{BvVQ>? M{nxcHNCVkeHUh?=
L-428 NIS1WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ|Lk[yJI5O MWjTRW5ITVJ?
SW954 NFfGSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD3OJdKSzVyPUKzMlY5KG6P NXrCPIpwW0GQR1XS
HO-1-N-1 NEDTcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPlNFBMUUN3ME2yN{44PyCwTR?= NGDUcnFUSU6JRWK=
CHP-126 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfMTlZJUUN3ME2yOE4yPCCwTR?= NVvRfFFLW0GQR1XS
HMV-II NEXZV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr6U|VXUUN3ME2yOE4{PCCwTR?= NYDjNJFtW0GQR1XS
NB10 NYHkOIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n1XGlEPTB;MkSuN|chdk1? MnXiV2FPT0WU
A172 NGrEfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n3S2lEPTB;MkSuO|Ehdk1? MYrTRW5ITVJ?
MONO-MAC-6 M1HDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnteG9KSzVyPUK0Mlg1KG6P MknLV2FPT0WU
NCI-H1650 NWTCWnUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ3LkSgcm0> NGfhbY1USU6JRWK=
NH-12 M{fVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TXOmlEPTB;MkWuOUBvVQ>? Mn\zV2FPT0WU
ML-2 NFnPdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfrW4FKSzVyPUK1Mlc1KG6P Mkn3V2FPT0WU
MZ2-MEL NYiyWJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i4SmlEPTB;Mk[uNlIhdk1? M2TpbXNCVkeHUh?=
COLO-684 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPPTWM2OD1{Nj60NUBvVQ>? NYTwfmJtW0GQR1XS
HuP-T4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHH[2NmUUN3ME2yO{4{KG6P M4n5SnNCVkeHUh?=
SW837 NYrIXVVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\3ZVUyUUN3ME2yO{43OiCwTR?= NEf2U2ZUSU6JRWK=
MDA-MB-231 NHvy[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3XTWM2OD1{Nz63PEBvVQ>? NGPPPIZUSU6JRWK=
KYSE-140 NWX0Oo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nBZWlEPTB;MkeuPVEhdk1? MWDTRW5ITVJ?
NOMO-1 NI\WdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\OcGRPUUN3ME2yPE43QCCwTR?= M1uyOHNCVkeHUh?=
GP5d MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXezfpNEUUN3ME2yPE44OiCwTR?= M2TZVXNCVkeHUh?=
COR-L105 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu2d2JKSzVyPUK5MlQzKG6P MVvTRW5ITVJ?
LS-411N NWPuOoxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWiwd5VnUUN3ME2yPU45QCCwTR?= NX3Yem1qW0GQR1XS
NY Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNyLkG4JI5O NGLsS5VUSU6JRWK=
NCI-H2030 M3znWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\qd3FKSzVyPUOwMlQ2KG6P NYXmVo5mW0GQR1XS
CCF-STTG1 NVzndJhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTKTHJCUUN3ME2zNU41OiCwTR?= NX3lU3FxW0GQR1XS
NCI-H1703 MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT6TWM2OD1|MT63PEBvVQ>? MYjTRW5ITVJ?
TUR NXzENYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jxRmlEPTB;M{KuNFMhdk1? MVnTRW5ITVJ?
NOS-1 NHvPUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTnTWM2OD1|Mj60OEBvVQ>? NF7uPXVUSU6JRWK=
A2058 NYrqSIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ezNGlEPTB;M{KuPFMhdk1? MYjTRW5ITVJ?
LCLC-103H NUXoSGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LqUmlEPTB;M{OuNlUhdk1? NX;zcFJWW0GQR1XS
NCI-H510A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHncFRKSzVyPUOzMlI4KG6P NWqwNZJJW0GQR1XS
BC-1 NHm4dndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTN|Lke3JI5O NXm5Nm9HW0GQR1XS
SK-CO-1 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN2LkCxJI5O NW\3eHFjW0GQR1XS
A673 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPwTm9KSzVyPUO0MlE4KG6P MXnTRW5ITVJ?
VM-CUB-1 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLxTWM2OD1|ND62PUBvVQ>? NGHDd4RUSU6JRWK=
HH NXjscnV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e1bWlEPTB;M{WuNFYhdk1? M1LxV3NCVkeHUh?=
CAL-27 NHXkOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfrTWM2OD1|NT6xOkBvVQ>? NHnTZmlUSU6JRWK=
NEC8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3PbnJZUUN3ME2zOU4{PyCwTR?= M1X1ZXNCVkeHUh?=
BxPC-3 M2Tl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfNW4ZJUUN3ME2zOk46OSCwTR?= Mln0V2FPT0WU
SNB75 NH;JXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXCSYg6UUN3ME2zO{4zPCCwTR?= MkjJV2FPT0WU
NB13 M3HmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV31ZlFEUUN3ME2zPE4zOyCwTR?= MUPTRW5ITVJ?
SK-OV-3 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN6Lke0JI5O MXnTRW5ITVJ?
ME-180 MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTHTWM2OD1|OD64JI5O M1nLXXNCVkeHUh?=
JiyoyeP-2003 NIDM[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v0cWlEPTB;M{muN|ghdk1? M2DVeHNCVkeHUh?=
LU-134-A Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRyLkCyJI5O MVfTRW5ITVJ?
LS-123 NHHOW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXKTWM2OD12MD6yPEBvVQ>? NWnqWHdzW0GQR1XS
COLO-800 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC1TWJ1UUN3ME20NE42PiCwTR?= MXLTRW5ITVJ?
LB831-BLC NFHxe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\kXGlEPTB;NEGuPFUhdk1? MkDkV2FPT0WU
NCI-H747 NEPHVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq5VHg{UUN3ME20Nk4zQCCwTR?= NITWU3dUSU6JRWK=
MZ7-mel MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR{Lk[2JI5O NXS3dpZrW0GQR1XS
GT3TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnL[VhEUUN3ME20Nk44OiCwTR?= M1rMbnNCVkeHUh?=
MOLT-16 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknOTWM2OD12Mz6wOUBvVQ>? NXXoV|d[W0GQR1XS
23132-87 NFjmRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR|LkC1JI5O NILxcJVUSU6JRWK=
PF-382 NHPofWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L4RWlEPTB;NESuNlIhdk1? NXnoN2plW0GQR1XS
ES3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjPc2ZKSzVyPUS0MlYhdk1? MnPhV2FPT0WU
SW756 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzpfndQUUN3ME20OU4yPCCwTR?= NHzoeoRUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作（参考用のみ）

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。 		52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4
CAS No. 95058-81-4
保管 粉
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579836 Recruiting Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer BeyondBio Inc. May 9 2018 Phase 1|Phase 2
NCT03449901 Recruiting Soft Tissue Sarcoma Washington University School of Medicine|Polaris Pharmaceuticals Inc. May 9 2018 Phase 2
NCT03422523 Recruiting Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma University Hospital Southampton NHS Foundation Trust|Hoffmann-La Roche May 9 2018 Phase 2
NCT02181634 Completed Cholangiocarcinoma PrECOG LLC.|Celgene Corporation December 9 2014 Phase 2
NCT01924260 Active not recruiting Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor Protocol Specific University of California Davis|National Cancer Institute (NCI)|Takeda August 9 2013 Phase 1
NCT01535924 Active not recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Beth Christian|Ohio State University Comprehensive Cancer Center February 9 2012 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答：

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

selleck catalog

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • BMH-21

    BMH-21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription.

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID